Abstract
Background: Psoriasis is a long-term inflammatory condition that impacts the skin and joints, caused by immune processes and systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a straightforward blood indicator that has been researched for its connection to disease severity, yet results remain inconsistent, particularly in Bangladesh. This research assesses how NLR relates to psoriasis severity, body surface area, duration, and additional markers of inflammation. Methods & Materials: This cross-sectional study enrolled 110 clinically diagnosed psoriasis patients and was carried out in 2025 at the Dermatology Department of Medical College for Women and Hospital, Dhaka, Bangladesh. Information was gathered on demographics, clinical features, and disease severity (PASI, BSA). Complete blood counts, ESR, CRP, and neutrophil-to-lymphocyte ratio (NLR) were measured from blood samples. To evaluate the relationships between NLR and markers of disease severity, statistical analyses comprised ANOVA and correlation tests. Ethical approval and informed consent were secured. Results: The majority of psoriasis patients were middle-aged (83.6%), male (56.4%), and lived in urban areas (65.5%), while 62.7% were overweight or obese. Chronic plaque psoriasis was the most common form (81.8%), and 45.5% of cases were of moderate severity. Blood counts fell within normal limits, yet the neutrophil-to-lymphocyte ratio (2.75 ± 1.10) and inflammatory markers (ESR, CRP) were elevated, rising notably as disease severity increased. NLR showed a positive correlation with PASI score, body surface area, disease duration, ESR, and CRP, suggesting a link to systemic inflammation and psoriasis severity. Conclusion: NLR rose in line with psoriasis severity and showed correlation with PASI, BSA, ESR, and CRP, suggesting it could serve as a simple and cost-effective marker of inflammation. Additional large-scale studies are required to confirm this.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 The Insight




PDF